Living up to the hype around GLP-1 obesity treatments is tough enough. But Eli Lilly needs to hit its own targets.
Related Posts
Jefferies downgrades Ford to underperform, says stock will struggle again in 2025
The new year could bring some more pullback for Ford, according to Jefferies.
U.S. will be ‘more pro-crypto’ after this election, no matter who wins, says Ripple CEO Garlinghouse
Ripple CEO Brad Garlinghouse is a big cynic on U.S. crypto regulation, but highly optimistic about the post-election environment around the corner.
Morgan Stanley has a new AI stock play, that’s applying the technology to law enforcement
This weapons manufacturer could be set up for continued gains in the months ahead, according to Morgan Stanley.